November 17, 2022
SEATTLE-November 16, 2022 -(BUSINESS WIRE)–Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $26 million Series A1 financing round. This brings total funding raised in 2022 to $86M for the company. FLG partner and CFO Greg Curhan assisted. Funds participating in the financing included Janus Henderson Investors, RA Capital Management, Adjuvant Capital, and founding investor GC Biopharma, a South Korean biopharmaceutical company specializing in the development and commercialization of vaccines, protein therapies, and therapeutic antibodies. The new funding will go to support clinical development of next-generation subunit vaccines.
Full press release is here.